You are here

Evaluating clinical, dietary and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic and histological remission.

Evaluating clinical, dietary and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic and histological remission. J Gastroenterol Hepatol. 2017 Feb 21;: Authors: Dhingra R, Kedia S, Venigalla PM, Kumar S, Singh N, Bopanna S, Singla V, Choudhury BN, Verma P, Tiwari V, Datta Gupta S, Makharia G, Ahuja V Abstract BACKGROUND: The literature on possible factors that could trigger a relapse in patients with ulcerative colitis (UC) in clinical, endoscopic and histological remission on long term follow up is scarce. AIM: To determine the relapse rate in…

Read More

ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis.

ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017 Jan 30;: Authors: Onodera M, Endo K, Kakuta Y, Kuroha M, Kimura T, Hiramoto K, Kanazawa Y, Negoro K, Shiga H, Kinouchi Y, Shimosegawa T Abstract BACKGROUND AND AIM: Tacrolimus is now considered to be one of the main therapeutic options for refractory ulcerative colitis. Both cytochrome P-450 3A5 (CYP3A5) and ATP-binding cassette subfamily B member 1 (ABCB1) associated with tacrolimus metabolism are known to…

Read More

Granulomas in mesenteric lymph nodes in Crohn’s disease patients with ileocolic resection are areassociated with younger age and transmural inflammation.

Granulomas in mesenteric lymph nodes in Crohn’s disease patients with ileocolic resection are areassociated with younger age and transmural inflammation. J Gastroenterol Hepatol. 2017 Jan 14;: Authors: Sun X, Yuan L, Li Y, Shen B, Xie H, Liu X Abstract BACKGROUND & AIMS: Mesenteric lymph nodes were usually removed during bowel resection surgery for Crohn’s disease (CD). Mesenteric lymph node (MLN) granuloma predicted postoperative disease recurrence in patients with CD after ileocolic resection (ICR). This study was aimed to identify factors associated with MLN granulomas in a cohort of CD…

Read More

Crosstalk Between Intestinal Epithelial Cell and Adaptive Immune Cell in Intestinal Mucosal Immunity.

Crosstalk Between Intestinal Epithelial Cell and Adaptive Immune Cell in Intestinal Mucosal Immunity. J Gastroenterol Hepatol. 2017 Jan 10;: Authors: Lu JT, Xu AT, Shen J, Ran ZH Abstract Constantly challenged by luminal bacteria, intestinal epithelium forms both a physical and biochemical defense against pathogens. Besides, intestinal epithelium senses dynamic and continuous changes in luminal environment and transmits signals to subjacent immune cells accordingly. It has been long accepted that adaptive immune cells fulfill their roles partly by modulating function of intestinal epithelial cells. Recent studies have brought up the…

Read More

SEROLOGIC ANTIBODIES IN RELATION TO OUTCOME IN POST-OPERATIVE CROHN’S DISEASE.

SEROLOGIC ANTIBODIES IN RELATION TO OUTCOME IN POST-OPERATIVE CROHN’S DISEASE. J Gastroenterol Hepatol. 2016 Dec 15;: Authors: Hamilton AL, Kamm MA, De Cruz P, Wright EK, Selvaraj F, Princen F, Gorelik A, Liew D, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Bell SJ, Brown SJ, Connell WR Abstract BACKGROUND: Disease recurs frequently after Crohn’s disease resection. The role of serological antimicrobial antibodies in predicting recurrence or as a marker of recurrence…

Read More

Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: a network meta-analysis.

Related Articles Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: a network meta-analysis. J Gastroenterol Hepatol. 2016 Dec 13;: Authors: Komaki Y, Komaki F, Micic D, Yamada A, Suzuki Y, Sakuraba A Abstract BACKGROUND AND AIM: A limited option of therapies is available for hospitalized patients with severe steroid refractory ulcerative colitis (UC). Furthermore, there exists a paucity of direct comparisons between them. To provide a comparative evaluation of the efficacy and safety of pharmacologic therapies, we conducted a network meta-analysis combined with a benefit-risk analysis of randomized controlled…

Read More

Infliximab induced tuberculosis in patients with UC: Experience from a country with high prevalence of tuberculosis-India.

Infliximab induced tuberculosis in patients with UC: Experience from a country with high prevalence of tuberculosis-India. J Gastroenterol Hepatol. 2016 Nov 28;: Authors: Puri AS, Desai D, Sood A, Sachdeva S Abstract BACKGROUND & AIM: Tuberculosis (TB) is a well-recognized iatrogenic adverse event following administration of biologic therapy given for a variety of clinical indications. There is paucity of data on the development of TB following use of biologics from countries with a high prevalence of TB. The aim of this study was to determine the risk of development of…

Read More

PRDX2 up-regulation in inflammatory bowel disease: friend or foe?

PRDX2 up-regulation in inflammatory bowel disease: friend or foe? J Gastroenterol Hepatol. 2016 Nov 21;: Authors: Senhaji N, Zaid Y, El Khalfi B, Fahimi M, Martin J, Badre W, Nadifi S, Soukri A Abstract BACKGROUND: Inflammatory bowel diseases (IBD) are chronic multi-factorial inflammatory disorders. Accumulating investigations have provided compelling evidence that describe the interplay of a complex genetic landscape and inappropriate inflammatory response to intestinal microbes in disease etiopathogenesis, but still pose challenges in diagnostic practices. METHOD: In this study, comparative proteomic analysis was conducted to identify disease specific proteins…

Read More

6-methylmercaptopurine induced leukocytopenia during thiopurine therapy in IBD patients.

Related Articles 6-methylmercaptopurine induced leukocytopenia during thiopurine therapy in IBD patients. J Gastroenterol Hepatol. 2016 Nov 16;: Authors: Meijer B, Kreijne JE, van Moorsel SA, Derijks LJ, Bouma G, Mulder CJ, Wong DR, van der Woude CJ, van Bodegraven AA, de Boer NK Abstract BACKGROUND: Thiopurines have a favorable benefit-risk ratio in the treatment of inflammatory bowel disease (IBD). A feared adverse event of thiopurine therapy is myelotoxicity, mostly occurring due to toxic concentrations of the pharmacologically active metabolites 6-thioguaninenucleotides. In oncology, myelosuppression has also been associated with elevated 6-methylmercaptopurine…

Read More

CDX2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis.

Related Articles CDX2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. J Gastroenterol Hepatol. 2016 Nov 11;: Authors: Tsuchiya K, Hayashi R, Fukushima K, Hibiya S, Horita N, Negi M, Itoh E, Akashi T, Eishi Y, Motoya S, Takeuchi Y, Kunisaki R, Fukunaga K, Nakamura S, Yoshimura N, Takazoe M, Iizuka B, Suzuki Y, Nagahori M, Watanabe M Abstract BACKGROUND AND AIMS: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with an intractable, recurrent course. Although the goal of UC therapy has…

Read More
<< Go Back